The global seasonal affective disorder therapeutics market is poised for significant expansion, with projections indicating a market value of USD 1.1 billion by the end of 2028. This growth, at a compound annual growth rate (CAGR) of 4.3% from 2022 to 2028, highlights the increasing awareness of SAD and the growing recognition of effective treatments. …
Tag Archives: Seasonal Affective Disorder Therapeutics Market
Global Seasonal Affective Disorder Therapeutics Market Set to Reach US$ 1.1 Billion by 2028, Forecasts Study
The global seasonal affective disorder therapeutics market is on a steady trajectory, projected to reach a valuation of US$ 1.1 billion by the end of 2028, according to a recent study. From 2022 to 2028, the market is expected to exhibit a compound annual growth rate (CAGR) of 4.3%. Currently valued at US$ 848.2 million, …
Seasonal Affective Disorder Therapeutics Market Poised for Growth, Anticipating US$ 1.1 Billion by 2028-FMI Projection
According to the study, medications known as selective serotonin reuptake inhibitors, or SSRIs, are frequently used to treat seasonal affective disorder. There are several branded and generic medications available on the seasonal affective disorder therapeutics market size however, buproban and citalopram continue to sell at a relatively higher rate. FMI credits this dominance to the widely accessible …
Seasonal Affective Disorder Therapeutics Market Set to Approach US$ 1.1 Billion by 2028-FMI Study
The global seasonal affective disorder therapeutics market is expected to grow at a 4.3% CAGR. The market is currently valued at US$ 848.2 million and is expected to reach US$ 1.1 billion by the end of 2028. Popular drugs preferred in seasonal affective disorder therapeutics include selective serotonin reuptake inhibitors (SSRIs), according to the report. While generics …
Seasonal Affective Disorder Therapeutics Market is Slated To Rise at a CAGR Of 4.3% during Forecast Period of 2022-2028
The seasonal affective disorder (SAD) therapeutics market is pegged at around US$ 848.2 million in 2022, with a modest Y-o-Y increase of 4.3% over 2022, according to a recent intelligence report by Future Market Insights. While drugs and devices collectively contribute to the consumption volume of seasonal affective disorder therapeutics, the latter will remain a major …